Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
about
CETP Inhibition: Past Failures and Future HopesNew Era of Lipid-Lowering DrugsHuman Neutrophil Peptide 1 Limits Hypercholesterolemia-induced Atherosclerosis by Increasing Hepatic LDL ClearanceInflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application.Cholesteryl ester transfer protein: ace of spades, queen of hearts, or the joker?Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Ethnicity and coronary artery disease: the role of high-density lipoprotein - a change in paradigm.Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.Anacetrapib as a potential cardioprotective strategy.Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination.The 10(th) Annual Cardiometabolic Health Congress General Session Highlights.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
P2860
Q26753158-89864AD1-94D1-4ADF-8AF7-0D81A49DDE77Q28072298-FC8D07BA-7998-40B7-98F9-4BDC926C24B1Q33809459-2403C2F5-C2D1-4908-BB7E-F65697AD3DA5Q34554918-7CD8AB96-696A-446C-B2DA-0703E22E1ADCQ35847625-479B32CB-1CD8-4416-80F6-12552CD59E63Q36197815-5F8D9A69-94C5-4F44-98AE-499E4FEEA460Q38544542-7CF166FD-7E5D-459A-BE57-70EC0B614B56Q39010254-9B84E7DE-036A-4984-9BA4-D290A53ECF63Q47162079-1846EA04-F579-4E1D-ADFB-D0893C05890BQ50271173-D1F66A88-F8E0-405D-A55A-2797832C18EDQ51306390-0263EA02-A8DC-403F-8C6E-60F6EE10EC40Q55401609-333B6FA0-EDFE-47CF-92E0-74D28AC3A0D1
P2860
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@ast
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@en
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@nl
type
label
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@ast
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@en
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@nl
prefLabel
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@ast
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@en
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@nl
P2093
P2860
P50
P356
P1476
Anacetrapib reduces progressio ...... icial effects of atorvastatin.
@en
P2093
Branko Simic
Elsbet Pieterman
Hans M G Princen
J Wouter Jukema
Jan B van Klinken
José W A van der Hoorn
Ko Willems van Dijk
Patrick C N Rensen
Sam J L van der Tuin
Susan Kühnast
P2860
P356
10.1093/EURHEARTJ/EHU319
P577
2014-08-20T00:00:00Z